BC Innovations | Aug 29, 2018
Distillery Therapeutics


INDICATION: Myotonic dystrophy type 1 (DM1) Cell culture and mouse studies suggest inhibiting miR-23b and miR-218 could help treat DM1. In myoblast cells from a DM1 patient, miR-23b and miR-218 antagomirs decreased disease-associated splicing defects...
BC Innovations | May 3, 2012
Targets & Mechanisms

Heat shock hits muscular dystrophy

Australian academics have used N-Gene Research Laboratories Inc. 's BGP-15 , a small molecule inducer of heat shock 70 kDa protein 1A in Phase IIb testing for diabetes, to increase muscle strength and survival in two...
BC Innovations | Feb 24, 2011
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular dystrophy ATPase Ca++ transporting cardiac muscle fast twitch 1 (ATP2A1; SERCA1); ATPase Ca++ transporting cardiac muscle slow twitch 2...
Items per page:
1 - 3 of 3